Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...

EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.

US drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration. The vaccine has been cleared to be used for males ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...

M-Trust – which is now in beta test release mode – is described by the company as a "cyber-physical trust platform." ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...